after enrollment, you will be randomly placed into one of two groups. one group receives the study drug zoldonrasib (named rmc-9805) together with the chosen chemotherapy, and the other group receives a matching placebo with the same chemotherapy.

you will not know which group you are in because the study is double‑blind.

before any treatment starts, a series of tests will be done to record your health status. these include a physical exam, blood tests, and imaging scans such as CT or MRI to evaluate the pancreatic cancer.

the results provide a reference point for later comparisons.

you will begin taking an oral tablet of zoldonrasib (rmc-9805) at a dose of 1200 mg each day, unless you were assigned to the placebo group, in which case you will take a tablet that looks the same but contains no active drug.

the tablet is swallowed with water and should be taken at the same time each day.

your doctor will select one of two standard chemotherapy regimens:

modified folfirinox (a combination of several drugs given intravenously every 2 weeks) or gemcitabine plus nab‑paclitaxel (two drugs given intravenously usually every 3 weeks).

the chemotherapy is administered in a clinic or infusion center.

you will continue to take the 1200 mg tablet each day for the duration of the study treatment.

if you experience any side effects, you should inform the study staff, but the dosing schedule remains daily unless instructed otherwise.

you will attend clinic visits regularly, typically before each chemotherapy cycle.

during these visits, blood will be drawn for routine laboratory tests, vital signs (blood pressure, heart rate) will be checked, and you will be asked about any new symptoms or side effects.

imaging scans (such as CT or MRI) will be performed at scheduled intervals, often every 8 weeks, to see whether the cancer is responding to treatment or progressing.

the scans are read by the study investigators using standard criteria.

if you develop side effects, the study team may adjust the dose of the chemotherapy or temporarily hold the oral tablet.

any changes will be explained to you and recorded in your study documents.

treatment with the oral tablet and chemotherapy will continue as long as the cancer does not worsen and the side effects remain manageable.

the study protocol allows treatment to stop if disease progression is confirmed or if toxicity becomes unacceptable.

when treatment ends, you will enter a follow‑up phase during which periodic visits may occur to collect information on overall survival and any long‑term effects.

these follow‑up visits are less frequent and focus on your health status after the study treatment.